Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma

被引：0
|
作者：
Coffey, David G. [1 ,2 ]
Landgren, Ola [3 ]
Xu, Yuexin [1 ]
Kazandjian, Dickran [4 ]
Pugh, Trevor J. [5 ]
Gnjatic, Sacha [6 ]
Warren, Edus H. [1 ,2 ]
Green, Damian J. [1 ,2 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA
[2] Univ Washington, Dept Med, Seattle, WA USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA
[4] NCI, Ctr Canc Res, Lymphoid Malignancies Branch, Multiple Myeloma Program,NIH, Bethesda, MD 20892 USA
[5] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Icahn Sch Med Mt Sinai, Human Immune Monitoring Ctr, New York, NY 10029 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-126222
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4367
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Mechanism of immunomodulatory drug resistance and novel therapeutic strategies in multiple myeloma
    Zuo, Xiaojia
    Liu, Dingsheng
    HEMATOLOGY, 2022, 27 (01) : 1110 - 1121
  • [2] Multiple myeloma stem cells may be responsible for conferring drug resistance
    不详
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (02) : 148 - 148
  • [3] Drug resistance in multiple myeloma
    Sonneveld, P
    Lokhorst, HM
    Vossebeld, P
    SEMINARS IN HEMATOLOGY, 1997, 34 (04) : 34 - 39
  • [4] Drug resistance in multiple myeloma
    Robak, Pawel
    Drozdz, Izabela
    Szemraj, Janusz
    Robak, Tadeusz
    CANCER TREATMENT REVIEWS, 2018, 70 : 199 - 208
  • [5] Drug resistance in multiple myeloma
    Sonneveld, P
    PATHOLOGIE BIOLOGIE, 1999, 47 (02): : 182 - 187
  • [6] A Molecular Analysis of Cereblon-Related Immunomodulatory Drug Resistance in Commpass Multiple Myeloma Patients
    Skerget, Sheri
    Benard, Brooks
    Christofferson, Austin
    Legendre, Christophe
    Aldrich, Jessica
    Nasser, Sara
    Yesil, Jennifer
    Auclair, Daniel
    Liang, Winnie
    Lonial, Sagar
    Keats, Jonathan J.
    BLOOD, 2017, 130
  • [7] Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
    Richardson, PG
    Schlossman, RL
    Weller, E
    Hideshima, T
    Mitsiades, C
    Davies, F
    LeBlanc, R
    Catley, LP
    Doss, D
    Kelly, K
    McKenney, M
    Mechlowicz, J
    Freeman, A
    Deocampo, R
    Rich, R
    Ryoo, JJ
    Chauhan, D
    Balinski, K
    Zeldis, J
    Anderson, KC
    BLOOD, 2002, 100 (09) : 3063 - 3067
  • [8] Multiple mechanisms contribute to acquired TRAIL resistance in multiple myeloma
    Ticona-Perez, Fany V.
    Chen, Xi
    Pandiella, Atanasio
    Diaz-Rodriguez, Elena
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
  • [9] Drug resistance and drug development in multiple myeloma
    Dalton, WS
    SEMINARS IN ONCOLOGY, 2002, 29 (06) : 21 - 25
  • [10] Cancer drug resistance in multiple myeloma
    Uckun, Fatih M.
    CANCER DRUG RESISTANCE, 2022, 5 (02) : 271 - 276
12345